

TRIAL SCHEDULE 2020-2021

	Immune Monitoring (IM) - Accredited	Immune Monitoring (Alternative Technologies) (IM(AT)) - Accredited	CD34 Stem Cell Enumeration (CD34) - Accredited	Leukaemia Immunophenotyping (LI) - Accredited	Leukaemia Diagnostic Interpretation (LDI) - Accredited	Paroxysmal Nocturnal Haemoglobinuria (PNH) - Accredited	Low Level Leucocyte Enumeration (LLL) - Accredited	Minimal Residual Disease for ALL by Flow Cytometry (MRD-ALL) - Accredited	Pilot Minimal Residual Disease for CLL by Flow Cytometry (MRD-CLL) - Not Accredited	Pilot Minimal Residual Disease for AML by Flow Cytometry (MRD-AML) - Not Accredited	Pilot Minimal Residual Disease for Plasma Cell Myeloma by Flow Cytometry (MRD-PCM) - Not Accredited	Pilot Haematological Malignancy Bone Marrow Aspirate Assessment (HMBAA) - Not Accredited	Pilot Cerebrospinal Fluid (CSF) Immunophenotyping Programme - Not Accredited
Planned trial issues per financial year	6	6	6	6	6	6	6	4	4	4	3	4	3
APRIL 2020			X	X		X	X		X		X		
MAY 2020	X	X			X			X					X
JUNE 2020			X	X		X	X			X		X	
JULY 2020	X	X			X				X				
AUGUST 2020			X	X		X	X	X			X		
SEPTEMBER 2020	X	X			X					X		X	X
OCTOBER 2020			X	X		X	X		X				
NOVEMBER 2020	X	X			X			X					
DECEMBER 2020			X	X		X	X			X	X	X	
JANUARY 2021	X	X			X				X				X
FEBRUARY 2021			X	X			X	X					
MARCH 2021	X	X			X	X				X		X	

Please note that this is a guide only. UK NEQAS for Leucocyte Immunophenotyping reserves the right to cancel or vary the number of shipments. Please note that your participation entitles you to the service and not the number of shipments.

Sheffield Teaching Hospitals NHS Foundation Trust, a UKAS proficiency testing provider No. 7804, operating UK NEQAS for Leucocyte Immunophenotyping.